Traws Pharma Publishes Key Clinical Efficacy Data For Rigosertib, Oncology Asset For Which Development And Commercialization Partners Are Being Actively Sought, In Patients With RDEB SCC

Author: Benzinga Newsdesk | June 03, 2025 07:03am

Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The paper, published in the British Journal of Dermatology1, details the first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease. The results indicated an overall response rate of 80%, with complete responses in 50% of evaluable patients.

Posted In: TRAW